Literature DB >> 10398823

Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue.

K Kubota1, M Tada, S Yamada, K Hori, S Saito, R Iwata, K Sato, H Fukuda, T Ido.   

Abstract

To evaluate the tumour imaging potential of fluorine-18 fluoromisonidazole (FMISO), we studied FMISO uptake in an experimental tumour model and examined the correlation between intratumoral distributions of FMISO, 14C-2-deoxyglucose (2DG) and 14C-methionine (Met). The study was performed using control rats with the AH109A tumour and rats with the same tumour under local hypoxia. Tumour uptake of FMISO was constant between 30 min and 2 h after injection, and the tumour to muscle ratio was 2 from 2 to 4 h. A tumour study with FMISO was scheduled at 2 h. Double-tracer autoradiography of the tumour demonstrated that in the areas of high FMISO uptake, there was low uptake of Met, while areas of low FMISO uptake showed high Met uptake. FMISO showed high grain density in the rim of the tumour surrounding the necrotic area. 2DG showed a more uniform distribution over the entire section of viable cells. The mean uptake of FMISO by hypoxic, radioresistant tumours was significantly higher than that by the control tumours (P<0.05), while both 2DG and Met uptake by the control tumours was higher than uptake by hypoxic tumours. When individual tumours were examined, the uptake of FMISO was inversely correlated with that of Met (r = -0.507, P<0.02), while 2DG showed almost uniform uptake with no significant correlation to FMISO. In conclusion, hypoxic and radioresistant tumours could be identified by increased FMISO uptake in our model, consistent with findings reported by others. We found a large overlap in the distribution of FMISO and 2DG within the tumour, but only a small overlap in the distribution of FMISO and Met. A combination of FMISO and other tracers in positron emission tomography or single-photon emission tomography studies might be more helpful than single-tracer studies in predicting the response of tumour tissues to radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398823     DOI: 10.1007/s002590050446

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

Review 1.  Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography.

Authors:  Craig K Abbey; Alexander D Borowsky; Jeffery P Gregg; Robert D Cardiff; Simon R Cherry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-04       Impact factor: 2.673

2.  Imaging of tumour hypoxia using PET and 18F-labelled tracers: biology meets technology.

Authors:  Tove Grönroos; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

3.  NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.

Authors:  Matthias T Wyss; Michael Honer; Pius A Schubiger; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-29       Impact factor: 9.236

4.  Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer.

Authors:  Juan Yang; ZhouXue Wu; Yao Chen; ChuanFei Hu; Dong Li; Yue Chen; Saber Imani; QingLian Wen; ShaoZhi Fu; JingBo Wu
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-01       Impact factor: 4.553

5.  Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma.

Authors:  Tomohiko Yamane; Masahiro Kikuchi; Shogo Shinohara; Michio Senda
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 6.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

7.  Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.

Authors:  Tove Grönroos; Lise Bentzen; Päivi Marjamäki; Rumi Murata; Michael R Horsman; Susanne Keiding; Olli Eskola; Merja Haaparanta; Heikki Minn; Olof Solin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

8.  pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?

Authors:  Bernd Gagel; Marc Piroth; Michael Pinkawa; Patrick Reinartz; Michael Zimny; Hans J Kaiser; Sven Stanzel; Branka Asadpour; Cengiz Demirel; Kurt Hamacher; Heinz H Coenen; Thomas Scholbach; Payam Maneschi; Ercole DiMartino; Michael J Eble
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

9.  Biological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma.

Authors:  Toshiyuki Hatano; Songji Zhao; Yan Zhao; Ken-Ichi Nishijima; Norihito Kuno; Hiroko Hanzawa; Takeshi Sakamoto; Nagara Tamaki; Yuji Kuge
Journal:  Int J Oncol       Date:  2013-01-18       Impact factor: 5.650

10.  Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry.

Authors:  L Dubois; W Landuyt; K Haustermans; P Dupont; G Bormans; P Vermaelen; P Flamen; E Verbeken; L Mortelmans
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.